{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:39:06Z","timestamp":1792712346351,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic renal cell carcinoma remains clinically challenging because of heterogeneous outcomes and limited predictive biomarkers for immunotherapy. We performed an explainable machine learning analysis using data from the multicenter retrospective Meet-URO 15 study, including 571 patients with metastatic renal cell carcinoma treated with second-line or later nivolumab. Clinical and inflammatory variables were used to develop classification models for disease control rate, progression-free survival at 3 and 9 months, and overall survival at 6, 18 and 24 months, as well as survival models for continuous progression-free and overall survival. Model performance was assessed using weighted F1-score for classification and concordance index for survival analysis, with interpretability provided through Shapley additive explanations. The best classification performance was observed for 6-month overall survival using a support vector machine model combined with minimum redundancy maximum relevance feature selection, achieving an F1-score of 0.81 on the test set and 0.77 in external validation. In survival analysis, random survival forest achieved a test-set concordance index of 0.68 for overall survival. Inflammatory indices, IMDC score, hemoglobin, lymphocytes and platelets consistently emerged as relevant prognostic features. These findings support explainable machine learning as a transparent approach to refine outcome prediction in immunotherapy-treated metastatic renal cell carcinoma.<\/jats:p>","DOI":"10.1038\/s41698-026-01576-x","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:45:54Z","timestamp":1782996354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study"],"prefix":"10.1038","volume":"10","author":[{"given":"Sara Elena","family":"Rebuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Miskovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Ramella","family":"Pollone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Laura Giulia","family":"Pedrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsela","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"1576_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","volume":"24","author":"YW Chen","year":"2023","unstructured":"Chen, Y. W. et al. Treatment landscape of renal cell carcinoma. Curr. Treat. Options Oncol. 24, 1889\u20131916, https:\/\/doi.org\/10.1007\/s11864-023-01161-5 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"key":"1576_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2351669","volume":"20","author":"SE Rebuzzi","year":"2024","unstructured":"Rebuzzi, S. E. et al. Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of \u201cpalateau\u201d. Hum. Vaccin Immunother. 20, 2351669, https:\/\/doi.org\/10.1080\/21645515.2024.2351669 (2024).","journal-title":"Hum. Vaccin Immunother."},{"key":"1576_CR3","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","volume":"110","author":"SB Guo","year":"2024","unstructured":"Guo, S. B. et al. Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study. Int J. Surg. 110, 4660\u20134671, https:\/\/doi.org\/10.1097\/JS9.0000000000001479 (2024).","journal-title":"Int J. Surg."},{"key":"1576_CR4","doi-asserted-by":"publisher","unstructured":"Oki, R. et al. Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review. Expert Rev. Anticancer Ther. Published online April (2025). https:\/\/doi.org\/10.1080\/14737140.2025.2491647.","DOI":"10.1080\/14737140.2025.2491647"},{"key":"1576_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/CCO.0000000000001138","volume":"37","author":"V Wong","year":"2025","unstructured":"Wong, V., Goodstein, T., Montenegro, G. B., Srinivasan, R. & Singer, E. A. Biomarkers in advanced renal cell carcinoma: current practice and future directions. Curr. Opin. Oncol. 37, 274\u2013282, https:\/\/doi.org\/10.1097\/CCO.0000000000001138 (2025).","journal-title":"Curr. Opin. Oncol."},{"key":"1576_CR6","doi-asserted-by":"publisher","unstructured":"Rebuzzi, S. E. et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) [published correction appears. Ther. Adv. Med. Oncol. 13, 17588359211019642 (2021). Published 2021 May 18. https:\/\/doi.org\/10.1177\/17588359211019642.","DOI":"10.1177\/17588359211019642"},{"key":"1576_CR7","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1634\/theoncologist.2019-0578","volume":"25","author":"DJ Martini","year":"2020","unstructured":"Martini, D. J. et al. Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist 25, e484\u2013e491, https:\/\/doi.org\/10.1634\/theoncologist.2019-0578 (2020).","journal-title":"Oncologist"},{"key":"1576_CR8","doi-asserted-by":"publisher","first-page":"e002851","DOI":"10.1136\/jitc-2021-002851","volume":"9","author":"JT Brown","year":"2021","unstructured":"Brown, J. T. et al. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J. Immunother. Cancer 9, e002851, https:\/\/doi.org\/10.1136\/jitc-2021-002851 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1576_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114048","volume":"204","author":"L Carril-Ajuria","year":"2024","unstructured":"Carril-Ajuria, L. et al. Validation of the lung immune prognostic index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. Eur. J. Cancer 204, 114048. https:\/\/doi.org\/10.1016\/j.ejca.2024.114048 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1576_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/1750743X.2025.2452145","volume":"17","author":"M Corian\u00f2","year":"2025","unstructured":"Corian\u00f2, M. et al. Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations. Immunotherapy 17, 25\u201335, https:\/\/doi.org\/10.1080\/1750743X.2025.2452145 (2025).","journal-title":"Immunotherapy"},{"key":"1576_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ccell.2022.09.012","volume":"40","author":"J Lipkova","year":"2022","unstructured":"Lipkova, J. et al. Artificial intelligence for multimodal data integration in oncology. Cancer Cell 40, 1095\u20131110, https:\/\/doi.org\/10.1016\/j.ccell.2022.09.012 (2022).","journal-title":"Cancer Cell"},{"key":"1576_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-025-00835-7","volume":"25","author":"EJ Najem","year":"2025","unstructured":"Najem, E. J., Shaikh, M. J. S., Shinagare, A. B. & Krajewski, K. M. Navigating advanced renal cell carcinoma in the era of artificial intelligence. Cancer Imaging 25, 16, https:\/\/doi.org\/10.1186\/s40644-025-00835-7 (2025).","journal-title":"Cancer Imaging"},{"key":"1576_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ucl.2023.06.002","volume":"51","author":"JE Knudsen","year":"2024","unstructured":"Knudsen, J. E., Rich, J. M. & Ma, R. Artificial intelligence in pathomics and genomics of renal cell carcinoma. Urol. Clin. North Am. 51, 47\u201362, https:\/\/doi.org\/10.1016\/j.ucl.2023.06.002 (2024).","journal-title":"Urol. Clin. North Am."},{"key":"1576_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ucl.2023.06.007","volume":"51","author":"AG Raman","year":"2024","unstructured":"Raman, A. G., Fisher, D., Yap, F., Oberai, A. & Duddalwar, V. A. Radiomics and artificial intelligence: renal cell carcinoma. Urol. Clin. North Am. 51, 35\u201345, https:\/\/doi.org\/10.1016\/j.ucl.2023.06.007 (2024).","journal-title":"Urol. Clin. North Am."},{"key":"1576_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","volume":"35","author":"A Prelaj","year":"2024","unstructured":"Prelaj, A. et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann. Oncol. 35, 29\u201365, https:\/\/doi.org\/10.1016\/j.annonc.2023.10.125 (2024).","journal-title":"Ann. Oncol."},{"key":"1576_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.euf.2021.04.024","volume":"7","author":"KS Rallis","year":"2021","unstructured":"Rallis, K. S. et al. Radiomics for renal cell carcinoma: predicting outcomes from immunotherapy and targeted therapies-a narrative review. Eur. Urol. Focus 7, 717\u2013721, https:\/\/doi.org\/10.1016\/j.euf.2021.04.024 (2021).","journal-title":"Eur. Urol. Focus"},{"key":"1576_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/CCI.20.00107","volume":"5","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Risk prediction using Bayesian networks: an immunotherapy case study in patients with metastatic renal cell carcinoma. JCO Clin. Cancer Inf. 5, 326\u2013337, https:\/\/doi.org\/10.1200\/CCI.20.00107 (2021).","journal-title":"JCO Clin. Cancer Inf."},{"key":"1576_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1021684","volume":"13","author":"E Barkan","year":"2023","unstructured":"Barkan, E. et al. Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma. Front Oncol. 13, 1021684. https:\/\/doi.org\/10.3389\/fonc.2023.1021684 (2023).","journal-title":"Front Oncol."},{"key":"1576_CR19","doi-asserted-by":"publisher","first-page":"e16513","DOI":"10.1200\/JCO.2023.41.16_suppl.e16513","volume":"41","author":"J Xiao","year":"2023","unstructured":"Xiao, J. et al. Association of a deep learning system with progression-free survival (PFS) in patients with renal cell carcinoma (RCC) treated with immune checkpoint blockades (ICBs). J. Clin. Oncol. 41, e16513\u2013e16513, https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16513 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1576_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104159","volume":"10","author":"A Elgebaly","year":"2025","unstructured":"Elgebaly, A., Abdelrahman, A. et al. Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy. ESMO Open 10, 104159. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104159 (2025).","journal-title":"ESMO Open"},{"key":"1576_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1181248","volume":"13","author":"TK Rugambwa","year":"2023","unstructured":"Rugambwa, T. K. et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 13, 1181248. https:\/\/doi.org\/10.3389\/fonc.2023.1181248 (2023).","journal-title":"Front Oncol."},{"key":"1576_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.639636","volume":"12","author":"Y Jian","year":"2021","unstructured":"Jian, Y. et al. Current advance of immune evasion mechanisms and tumor microenvironment in renal cell carcinoma. Front Immunol. 12, 639636 (2021).","journal-title":"Front Immunol."},{"key":"1576_CR23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/jcm9040930","volume":"9","author":"A Mennitto","year":"2020","unstructured":"Mennitto, A. et al. Angiogenesis and immunity in renal carcinoma: can we turn an unhappy relationship into a happy marriage? J. Clin. Med 9, 930 (2020).","journal-title":"J. Clin. Med"},{"key":"1576_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bju.16336","volume":"134","author":"T Yanagisawa","year":"2024","unstructured":"Yanagisawa, T. et al. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. BJU Int. 134, 323\u2013336, https:\/\/doi.org\/10.1111\/bju.16336 (2024).","journal-title":"BJU Int."},{"key":"1576_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12319-1","volume":"24","author":"SE Rebuzzi","year":"2024","unstructured":"Rebuzzi, S. E. et al. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study). BMC Cancer 24, 757, https:\/\/doi.org\/10.1186\/s12885-024-12319-1 (2024).","journal-title":"BMC Cancer"},{"key":"1576_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1-update and clarification: From the RECIST committee. Eur. J. Cancer 62, 132\u2013137, https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1576_CR27","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"1576_CR28","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1109\/TPAMI.2005.159","volume":"27","author":"H Peng","year":"2005","unstructured":"Peng, H., Long, F. & Ding, C. Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans. Pattern Anal. Mach. Intell. 27, 1226\u20131238, https:\/\/doi.org\/10.1109\/TPAMI.2005.159 (2005).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"1576_CR29","first-page":"1157","volume":"3","author":"I Guyon","year":"2003","unstructured":"Guyon, I. & Elisseeff, A. An introduction to variable and feature selection. J. Mach. Learn. Res. 3, 1157\u20131182 (2003).","journal-title":"J. Mach. Learn. Res."},{"key":"1576_CR30","doi-asserted-by":"crossref","unstructured":"Chen, T. & Guestrin, C. Xgboost: a scalable tree boosting system. in Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, KDD \u201916, (New York, NY, USA), p. 785\u2013794 (Association for Computing Machinery, 2016).","DOI":"10.1145\/2939672.2939785"},{"key":"1576_CR31","unstructured":"Kleinbaum, D. Logistic Regression: A Self-Learning Text. Statistics for Biology and Health (Springer New York, 2013)."},{"key":"1576_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Random forests. Mach. Learn. 45, 5\u201332 (2001).","journal-title":"Mach. Learn."},{"key":"1576_CR33","unstructured":"Haykin, S. Neural Networks: A Comprehensive Foundation 2nd edn (Prentice Hall PTR, 1998)."},{"key":"1576_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1023\/A:1022627411411","volume":"20","author":"C Cortes","year":"1995","unstructured":"Cortes, C. & Vapnik, V. Support-vector networks. Mach. Learn. 20, 273\u2013297 (1995).","journal-title":"Mach. Learn."},{"key":"1576_CR35","doi-asserted-by":"crossref","unstructured":"Freund, Y., & Schapire, R. E. A decision-theoretic generalization of on-line learning and an application to boosting,\u201d in Proceedings of the Second European Conference on Computational Learning Theory, EuroCOLT \u201995, (Berlin, Heidelberg), 23\u201337 (Springer-Verlag, 1995).","DOI":"10.1007\/3-540-59119-2_166"},{"key":"1576_CR36","doi-asserted-by":"crossref","unstructured":"Geurts, P., Ernst, D., & Wehenkel, L. Extremely randomized trees. Mach. Learn. 63, 3\u201342 (2006).","DOI":"10.1007\/s10994-006-6226-1"},{"key":"1576_CR37","unstructured":"Ke, G. et al. Lightgbm: a highly efficient gradient boosting decision tree. in Proceedings of the 31st International Conference on Neural Information Processing Systems, NIPS\u201917, (Red Hook, NY, USA), 3149\u20133157 (Curran Associates Inc., 2017)"},{"key":"1576_CR38","doi-asserted-by":"crossref","unstructured":"Leblanc, M. & Crowley, J. Survival trees by goodness of split. J. Am. Stat. Assoc 88, 457\u2013467 (1993).","DOI":"10.1080\/01621459.1993.10476296"},{"key":"1576_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1214\/08-AOAS169","volume":"2","author":"H Ishwaran","year":"2008","unstructured":"Ishwaran, H., Kogalur, U., Blackstone, E. & Lauer, M. Random survival forests. Ann. Appl. Stat. 2, 12 (2008).","journal-title":"Ann. Appl. Stat."},{"key":"1576_CR40","doi-asserted-by":"crossref","unstructured":"Friedman, J. Greedy function approximation: a gradient boosting machine. Ann. Stat. 29, 11 (2000).","DOI":"10.1214\/aos\/1013203451"},{"key":"1576_CR41","doi-asserted-by":"crossref","unstructured":"P\u00f6lsterl, S., Navab, N. & Katouzian, A. Fast training of support vector machines for survival analysis. In Machine Learning and Knowledge Discovery in Databases: European Conference, ECML PKDD 2015, Porto, Portugal, Proceedings, Part I, Lecture Notes in Computer Science, Vol. 9285, 243\u2013259 (Springer, Cham, 2015).","DOI":"10.1007\/978-3-319-23525-7_15"},{"key":"1576_CR42","first-page":"1","volume":"21","author":"S P\u00f6lsterl","year":"2020","unstructured":"P\u00f6lsterl, S. scikit-survival: A library for time-to-event analysis built on top of scikit-learn. J. Mach. Learn Res. 21, 1\u20136 (2020).","journal-title":"J. Mach. Learn Res."},{"key":"1576_CR43","unstructured":"Lundberg, S. M. & Lee, S. I. A unified approach to interpreting model predictions. Adv. Neural Inform. Process. Syst. 2017-Decem, 4766\u20134775 (2017)."},{"key":"1576_CR44","unstructured":"Lundberg, S. Shap Python library. Software Library. Available at https:\/\/shap.readthedocs.io\/en\/latest\/index.html."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01576-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01576-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01576-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:58:46Z","timestamp":1792709926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01576-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01576-x","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.E.R. reports honoraria for speaking at scientific events and travel\/accommodation fees for scientific meetings from BMS, Ipsen, Eisai, Astellas, Amgen, and GSK. V.M. is Guest Editor of the \u201cAI agents in oncology\u201d collection in npj Precision Oncology. V.M. was not involved in the journal\u2019s review of, or decisions related to, this manuscript. S.B. reports honoraria for speaking at scientific events and advisory roles from AstraZeneca, BMS, Ipsen, Merck, Eisai, MSD, Novartis, Gentili, Astellas, and Pfizer, and research funding from Novartis and Pfizer. G.F. serves on advisory boards for Astellas, Janssen, Pfizer, Bayer, MSD, and Merck, and received travel accommodation from Astellas, Janssen, and Bayer. PR reports advisory board and consultancy roles for MSD, Janssen, AstraZeneca, BMS, and Gilead. G.L.B. reports personal fees for advisory boards from Accord, AstraZeneca, Amgen, and Merck, and speaker bureau activities for Astellas, AstraZeneca, Amgen, Bayer, Merck, and Pfizer. A.G. is co-founder of OncoFlow by UMA Advisory Ltd. A.L.G.P. is co-founding partner of Agade srl and AllyArm srl and has conducted seminars for Novartis and collaborated in research and educational projects funded by public and private institutions. The other authors do not have a competing interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"402"}}